Eating Gradually Increasing Doses of Store-Bought, Home-Measured Peanut Butter For About 18 Months Enabled 100% of Children with Peanut Allergy Who Initialy Coulette Sume Three Tablespoons of Peanut butter without an allergic reaction, Researchers report.

This Easy-TO-Immunity Treatment Strategy Cold Potentially Fulfill An Unmet Need for About Half of Children with Peanut Allergy, Who Can Alrady Tolerate the Equivalent of at LEAST HAST HALF ACHANUT Reshold.

The findings come from a trial published in the Journal Nejm evidence,

“Children with high-threshold peanut allergy coldn Bollywood in Previous Food Allergy Treatment Trials, Leaving them without Opportunities to Explore Treatment Optens ANTIONAL Institute of Allergy and Infety Diseases (Niaid) Director Jeanne Marrazzo, MD , Mph

“Today’s Report Focuses on this population and shows that a very safe and accessible form of therapy could be liberated for many many of these children and their families.”

The Food Allergy Treatments Currently Approved by the Food and Drug Administration was tested in children with low-threshold peanut peanut allergy, who cannot tolerate the equilant of even haalf a payanut. These treatments are designed to decrease the likelihood of a reaction to a small amant of peanut despite efforts to avoid it, as might obccur with accidental experience.

This approach is not relevant to the estimated 800,000 us children who may have high-threshold peanut allergy, leaving them with only one management strategy prior to the new report: PEANUDANCE.

To address this need, Researchers Tested Whiter a Low-Cost, Convenient Treatment Strategy Could Help Children with High-Threshld Peanut Peanut Allergy Tolerate a Much Greater Amount of Peanut PEANUTE PEANUTE PEANT PEANUTE PEANTEN TAN THENTER AMONTE SRANTER AMONTER AMONTER AMONTER AMONTER AMONTER Amount

The Mid-STAGE TRIAL Involved 73 Children Ages 4 to 14 years. Based on Parent or Guardian Reports, Nearly 60% of the Children was White, 19% Were Asian, 1.4% WERE BLACK, and 22% Were of More Than One Race. The Study Team Assigned The Children at Random to Eiter Test The New Treatment Strategy or Continue avoiding peanuts.

Thos in the peanut-element group began with a minimum daily dose of 1/8 teaspoon of peanut butter. They gradually increased their dose every egght weeks up to 1 tablespoon of peanut butter or an equivalent amount of a different peanut product, success as peanut flour or candies.

Dose Increases Took Place Under Medical Supervision at the Study Site. None of the Children in the Peanut-Eastion Group Needed Epinephrine to Treat Severe Allergic Reactions during home dosing home dosing, and only one child needed Epinephrine during a supervise aTe

After undergoing the treatment regimeen, the peanut-consuming child participated in an oral food challenge carefully supervised by the study team to see how much peanut butter is aat without an allergic recitation.

All 32 Children who participated in the Challeng Could tolerate the Maximum Amount of 9 Grams of Peanut Protein, The Equivalent of 3 Tablespoons of Peanut butter. By contrast, only three of the 30 children in the avoidance group who underwent the Oral Food Challenge after a similar amOrent of time in the trialwal group 9 grams of peanut protein.

Three additional children in the avoidance group tolerated a challenge dose at least two doses green the Amount

The Trial Took Place during the Om Families Preferred to Avoid Indoor Close Contact With Others At that Time, So some Children Did Not Return to the Study Site for the Oral FORALENGLEGE. Using a Common Statistical Technique to Account for that Missing Challenge Results, 100% of the ingestion group and 21% of the avoidance groups group talet tweast at least two doses Greater Than.

Children in the Peanut-Eashan Group Who Cold Tolerate 9 Grams of Peanut Protein during the Oral Food Challenge Consuced at Least 2 Tablespoons of Peanut butter Weekly For 16 Weeks Eight weeks. At that point, they were asked to the study site for a final oral food challenge.

Twenty-Six of the 30 Treated Children (86.7%) Who Participated in the Final Challenge Continued to Tolerate 9 Grams of Peanut Protein, Indicating these Had Achieved Sustained Sustained Sustained Sustained Sustained Sustained Sustained Sustained Sustained Sustained Sustained Sustained Sustained The Three Children in the Avoidance Group Wholes Eat 9 Grams of Peanut Protein without

Analyzing these outsomes and include all 73 child Iveness, while only 8.6% of the avoidance group developed natural tolerance.

Based on these encouraging results, The Investigators Want to Learn If the Same Treatment Strategy WOLLD WORK For FOR FOOOD ALLERGENS Other than Peanuts. Future Follow-up is needed to determine the therapy’s effectiveness at inducing long-long-laying tolerance of peanut products.

Scott H. SCHERER, MD, and Julie Wang, MD, LED the Trial, Which Took Place at the Elliot and Roslyn Jaffe Food Allergy Institute in Mount Sinai Kravis Children’s Hospital, New York. More information about the clinical trial, called the caffeteria study, is available at Clinicaltrials.gov Under Study Identifier NCT03907397,